Shield Therapeutics (STX) RNS Announcements

Add to Alert list
Date Time Source Announcement
03 Dec 2025 07:04 AM
RNS
Amends Senior Secured Debt Financing
14 Nov 2025 07:03 AM
RNS
Initiation of a Phase II Clinical Trial in Japan
11 Nov 2025 07:00 AM
RNS
ACCRUFeR Pediatric PK Results to be Presented
07 Nov 2025 07:03 AM
RNS
ACCRUFeR receives Authorisation by Korean Ministry
23 Oct 2025 07:00 AM
RNS
Q3 2025 Trading Update
14 Oct 2025 03:01 PM
RNS
Grant of Share Options to Chief Executive Officer
01 Oct 2025 08:00 AM
RNS
Total Voting Rights
01 Oct 2025 07:02 AM
RNS
Positive efficacy and tolerance in pediatric trial
15 Sep 2025 07:00 AM
RNS
£1.5 million placing supporting growth of ACCRUFeR
04 Sep 2025 07:03 AM
RNS
ACCRUFeR® assigned Priority Review in US by FDA
03 Sep 2025 02:17 PM
RNS
Interim results for the six months ended 30 Jun 25
27 Aug 2025 07:13 AM
RNS
Data published -European Journal of Heart Failure
21 Aug 2025 12:06 PM
RNS
Interim results for the six months ended 30 Jun 25
23 Jul 2025 07:00 AM
RNS
Q2 2025 Trading Update
22 May 2025 05:06 PM
RNS
Result of AGM
24 Apr 2025 07:06 AM
RNS
Audited results for the year ended 31 Dec 2024
22 Apr 2025 07:01 AM
RNS
Licence Agreement in Japan for ACCRUFeR®
17 Apr 2025 11:23 AM
RNS
Q1 2025 Trading Update
11 Mar 2025 07:00 AM
RNS
ACCRUFeR® launched in Canada
13 Feb 2025 04:15 PM
RNS
PDMR Transaction Notification
13 Feb 2025 07:00 AM
RNS
Grant of Share Options
05 Feb 2025 07:00 AM
RNS
Unaudited full year trading update
27 Jan 2025 07:00 AM
RNS
Anders Lundstrom appointed CEO
24 Dec 2024 11:25 AM
RNS
Result of General Meeting & Total Voting Rights
23 Dec 2024 07:00 AM
RNS
Results of RetailBook Offer
06 Dec 2024 11:31 AM
RNS
RetailBook Offer
06 Dec 2024 11:30 AM
RNS
Subscription by AOP Health to raise US$10 million
21 Nov 2024 11:15 AM
EQS
Hardman & Co Investor Forum Research on Shiel...
21 Nov 2024 07:00 AM
RNS
Business Update
11 Nov 2024 02:00 PM
EQS
Hardman & Co Video Event: Shield Therapeutics...
29 Oct 2024 07:00 AM
RNS
Q3 Trading Update
25 Sep 2024 07:00 AM
RNS
Results from Phase 3 paediatric study
11 Sep 2024 12:25 PM
EQS
Hardman & Co Research on Shield Therapeutics ...
04 Sep 2024 07:00 AM
RNS
Interim results
27 Aug 2024 07:00 AM
RNS
ACCRUFeR® Approved by Health Canada
14 Aug 2024 07:00 AM
RNS
Notice of interim results
24 Jul 2024 07:01 AM
RNS
Unaudited Q2 2024 Trading Update
24 Jul 2024 07:00 AM
RNS
Directorate Change
03 Jul 2024 07:00 AM
RNS
$5.7m Milestone Monetization Agreement with AOP
20 Jun 2024 04:25 PM
RNS
Results of 2024 Annual General Meeting
28 May 2024 07:00 AM
RNS
New Drug Application for Accrufer® in South Korea
23 May 2024 07:15 AM
EQS
Hardman & Co: Shield Therapeutics (STX): Cash...
10 May 2024 03:30 PM
RNS
Audited results for the year ended 31 Dec 2023
30 Apr 2024 07:00 AM
RNS
Business Update for Q1 2024
16 Apr 2024 07:00 AM
RNS
Notice of Results
21 Feb 2024 07:00 AM
RNS
Unaudited Full Year Trading Update
09 Jan 2024 07:00 AM
RNS
Appointment of new Chief Financial Officer
07 Dec 2023 07:00 AM
RNS
Q3 2023 U.S. Commercial Highlights
27 Nov 2023 05:24 PM
RNS
PDMR Transaction Notification
15 Nov 2023 07:30 AM
EQS
Hardman & Co Research on Shield Therapeutics ...

Shield Therapeutics is a pharmaceutical company that develops medicines to treat iron deficiency.

Shield Therapeutics share price is listed on LSE under the ticker STX.

UK 100

Latest directors dealings